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ABSTRACT 
The aim of our study is to determine whether mexiletine, a CYP1A2 inhibitor, altered 
the pharmacokinetics and pharmacodynamics of tizanidine. Pharmacokinetics of 
tizanidine was examined in an open-label study in 12 healthy subjects after a single 
dose of tizanidine (2 mg) with and without mexiletine coadministration (50 mg, 3 times 
as a pre-treatment for a day and 2 times on the study day). Compared with tizanidine 
alone, mexiletine coadministration increased the peak plasma concentration (1.8 ± 0.8 
vs. 5.3 ± 1.8 ng/mL), area under the curve (4.5 ± 2.2 vs. 15.4 ± 6.5 ng•h/mL) and the 
half-life (1.3 ± 0.2 vs. 1.8 ± 0.7 h) of tizanidine, respectively (P<0.05). Reduction in 
systolic blood pressure (−10 ± 8 vs. −24 ± 7 mmHg) and diastolic blood pressure (−10 ± 
7 vs. −18 ± 8 mmHg) after tizanidine administration were also significantly enhanced 
by coadministration of mexiletine (P<0.01). Of the 15 patients treated with tizanidine 
and mexiletine, 4 suffered tizanidine-induced adverse effects such as drowsiness and 
dry mouth in the retrospective survey. Present results suggested that coadministration of 
mexiletine increased blood tizanidine concentrations and enhanced tizanidine 
pharmacodynamics in terms of reduction in blood pressure and adverse symptoms.  
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INTRODUCTION  
Tizanidine, an antispastic agent, is a sensitive substrate for cytochrome P450 (CYP) 
1A2 as compared to theophylline and caffeine.1−3 Recent studies revealed that 
coadministration of potent CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine 
with tizanidine induced the adverse effects of tizanidine (hypotension, low heart rate 
(HR), anuresis, drowsiness and speech disorders) accompanied with marked elevation 
in plasma tizanidine concentration.4−7 These combination therapies have been identified 
as contraindications in Japan.6−8 
Mexiletine, a class 1b antiarrhythmic agent, is known to be a potent CYP1A2 
inhibitor with a smaller inhibition constant as compared to ciprofloxacin in vitro.9, 10 It 
has also been reported that coadministration of mexiletine increased plasma 
theophylline concentration via CYP1A2 inhibition in patients and healthy subjects.11−15 
These findings suggest that mexiletine may alter tizanidine pharmacokinetics when both 
drugs are administered simultaneously. 
This combination is sometimes used for the treatment of painful neuropathies. 
Although the drug interaction between mexiletine and tizanidine is stated in package 
inserts of pharmaceutical products of tizanidine hydrochloride,8 the magnitude and 
clinical effect of this interaction is unclear. To clarify this issue, we investigated the 
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effects of mexiletine coadministration on the pharmacokinetics and pharmacodynamics 
of tizanidine in healthy subjects. Adverse effects were also surveyed retrospectively in 
the medical records of patients treated with this combination therapy. 
 
MATERIALS AND METHODS 
Subjects 
Twelve healthy male subjects (29 ± 5 y; 69.9 ± 12.1 kg) including 5 smokers 
participated in the study (Table 1). We did not exclude smokers whose CYP1A2 
activities may have potentially been induced,16 because we would like to examine the 
effects of smoking on the drug interaction in subgroup analyses (smokers and 
non-smokers). The subjects were considered healthy by their medical history, physical 
examination and routine laboratory tests before participating in the study. For safety 
reasons, subjects with systolic blood pressure (SBP) less than 110 mmHg and/or 
CYP1A2 gene mutation (−3113G→A) were excluded from the study. None of the 
subjects received medication at least 2 weeks prior to the study. 
Study design 
An open-label study with washout periods of >5 days was performed. Subjects 
ingested 2 mg tizanidine (Ternelin® Novartis Pharma, Basel, Switzerland) at 09:00 
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(control phase) on the study day. After the washout period, the subjects ingested 50 mg 
mexiletine hydrochloride (Mexitil® capsule, Nippon Boehringer Ingelheim, Tokyo, 
Japan; 3 times a day; at 08:00, 12:00 and 20:00) as pre-treatment. For safety reasons, 
pre-treatment with mexiletine was limited for one day. On the study day, subjects 
ingested 50 mg mexiletine 2 times a day; at 08:00 and 12:00 and 2 mg tizanidine at 
09:00 (mexiletine phase). A low-fat meal was served at 07:00 and 12:00 as breakfast 
and lunch, respectively, on the study day. Grapefruit juice and alcohol and/or 
caffeine-containing beverages were not allowed during the study, 7 days and 1 day prior 
to the study, respectively.  
Venous blood samples for determining plasma concentrations of tizanidine and 
mexiletine were collected immediately before and 0.5, 1, 2, 3 and 5 h after tizanidine 
administration. Urine sample was collected 8 h after tizanidine dosing. Urine and 
plasma separated from each whole blood sample was stored at −20°C until analys es. 
SBP, diastolic blood pressure (DBP) and HR were measured immediately after each 
blood sampling, for up to 5 h after tizanidine administration. An automatic oscillometric 
blood pressure monitor (HEM-1000; Omron Healthcare, Kyoto, Japan) was used for 
these measurements.  
The study protocol was approved by the Ethics Committee of the University of 
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Tsukuba, (Tsukuba, Japan). Written informed consent was obtained from all subjects. 
Determination of drug concentrations in plasma and urine 
Plasma and urine concentrations of tizanidine were determined using an API 3000 
liquid chromatography-tandem mass spectrometry system (Applied Biosystems, Tokyo, 
Japan) according to the method of Nirogi et al with minor modification.17 Briefly, to 300 
µL of plasma or urine, 25 µL of internal standard (IS) (tamsulosin, 10 or 50 ng/mL, 
Toronto Research Chemicals, North York, Canada) and 30 µL of sodium hydroxide 
solution (0.1%) was added and vortexed for 30 s. To extract tizanidine and IS, diethyl 
ether/dichloromethane (7/3, v/v) was vortexed with the mixture for 3 min. The organic 
layer was evaporated to dryness under a stream of nitrogen. The dried extract was 
reconstituted with 100 µL of mobile phase and the aliquot (20 µL) injected into the 
chromatograph. The samples were separated on a C8 column (Inertsil C8, 4.6mm 
i.d.×150 mm, GL Sciences, Tokyo, Japan) using high-performance liquid 
chromatography (HPLC; LC-10AD VP system, Shimadzu, Kyoto, Japan). The 
analytical column was maintained at 40°C. The HPLC mobile phase consisted of 10 
mM ammonium formate and methanol (10:90, v/v), and the flow rate was set at 1.2 mL/ 
min. Multiple reaction monitoring was used for mass spectrometric detection. Positive 
ionization mode was used in a heated nebulizer interface operating with the 
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nebulizer-gas temperature set at 350°C. The monitored m/z for tizanidine and IS were 
254.0/44.0 and 409.0/228.0, respectively. The ranges for tizanidine quantification in 
plasma and urine were 0.1−10 ng/mL and 0.5−50 ng/mL, respectively. Corresponding 
within-day coefficient of variations (CVs) of tizanidine assay were 4.3−5.1% for plasma 
and 1.5−9.8% for urine.  
The plasma concentrations of mexiletine were determined using HPLC (LC-10AT VP 
system, Shimadzu) in Mitsubishi Chemical Medience (Tokyo, Japan). The methods are 
described in the previous report by Mastropaolo et al.18 The lower limit of quantification 
was 0.1 µg/mL and within-day CVs for 0.1−2.0 µg/mL were 1.5−6.7%.  
All chemicals used for the assays were of analytical reagent grade. 
Pharmacokinetic and pharmacodynamic analyses 
Pharmacokinetic parameters such as peak concentration in plasma (Cmax), time to 
Cmax (tmax) and elimination half-life (t1/2) of tizanidine were calculated from plasma 
concentration-time data. Area under the plasma concentration time curve (AUC) was 
calculated by the trapezoidal method. Apparent oral clearance (CL/F) was calculated as 
dose/AUC0–5. Non-renal clearance (CLNR/F) was calculated as the difference between 
CL/F and Renal clearance (CLR/F). The pharmacokinetics of mexiletine was 
characterized by Cmax and AUC from 0 to 6 h after the morning dose of mexiletine in 
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study day. A part of plasma mexiletine concentrations within the detector limit were 
predicted with a Bayesian estimate using Higuchi’s Bayesian program, PEDA VB ver. 
1.0.0.58.19  
Area under the effects (SBP, DBP and HR) versus time curves after administration of 
tizanidine were assessed as the pharmacodynamic marker for tizanidine. 
Genotyping of CYP1A2 
Genomic DNA was isolated from peripheral blood using the QIAamp DNA Mini Kit 
(Qiagen GmbH, Hilden, Germany). The genotyping of CYP1A2 at the position of 
−3113G→A was conducted by polymerase chain reaction-restriction fragment length 
polymorphism according to the method of Chen et al.20 This single nucleotide 
polymorphism is associated with low CYP1A2 activity.  
Retrospective survey 
We investigated medical records obtained from 1,563 patients treated with 
tizanidine in Tsukuba University Hospital and found 15 patients who received 
mexiletine simultaneously. The episodes associated with tizanidine administration (e.g. 
low blood pressure, low HR, drowsiness, anuresis and dry mouth), dosage, 
coadministration periods for tizanidine and mexiletine and patient characteristics (e.g. 
age, sex, body weight, disease, laboratory data and smoking status) were recorded. 
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Statistical analyses 
Data are expressed as percentages, ranges, mean ± SD or 95% CI. Pharmacokinetic 
and pharmacodynamic data between control and mexiletine phases in healthy subjects 
were compared by paired Student’s t-test. The plasma concentration-time profiles of 
tizanidine and blood pressure-time profiles were compared by repeated-measures 
ANOVA. Comparing the patients’ blood pressures with and without coadministration of 
tizanidine and mexiletine was conducted by paired Student’s t-test. Difference was 
considered statistically significant when P value was less than 0.05.  
 
RESULTS 
Pharmacokinetics of tizanidine and mexiletine 
The pharmacokinetic profile and parameters of tizanidine are compared between 
control and mexiletine phase in Fig. 1 and Table 2. Plasma tizanidine concentrations for 
mexiletine phase were significantly higher than control. Mean AUC0–5 and Cmax of 
tizanidine for the mexiletine phase were 3.6-fold and 3.1-fold higher than control (Table 
2). The mean t1/2 of tizanidine for the mexiletine phase was prolonged by 1.4-fold as 
compared to control (Table 2). The CL/F and CLNR/F of tizanidine for the mexiletine 
phase decreased to one-third of control, although CLR/F remained unchanged (Table 2).  
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The pharmacokinetic parameters of tizanidine were compared between smokers and 
non-smokers. No significant difference in any parameters either for control and 
mexiletine phase was observed between two groups (data not shown).  
Plasma mexiletine concentrations were determined on the study day. Cmax and 
estimated AUC0–6 of mexiletine were 0.21 ± 0.04 µg/mL and 0.86 ± 0.19 µg•h/mL, 
respectively (Table 1).  
Change in blood pressure and HR 
Changes in blood pressures and HR between the control and mexiletine phases were 
compared (Fig. 2 and Table 3). SBP and DBP in the mexiletine phase were significantly 
lower than those in control, respectively. Both pharmacodynamic markers for mexiletine 
phase were significantly lower than control (P<0.05) (Table 3). Reduction in SBP (−10 
± 8 vs. −24 ± 7 mmHg) and DBP (−10 ± 7 vs. −18 ± 8 mmHg) after tizanidine 
administration were also significantly enhanced by coadministration of mexiletine 
(P<0.01). Three subjects had drowsiness in the control phase and 10 subjects had 
drowsiness, dry mouth and/or dizziness 1−3 h after tizanidine administration in the 
mexiletine phase.  
Clinical survey from patients 
Of the 1,563 patients treated with tizanidine, 15 patients (male/female: 9/6; 60 ± 13 y; 
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61.2 ± 12.8 kg; 8 non-smokers, 6 smokers and 1 unknown) had been coadministered 
mexiletine. Their daily doses of tizanidine and mexiletine, and the coadministration 
periods were 46.2 (27.8−77.3) µg/kg and 3.9 (1.8−6.0) mg/kg, and 40 (1−791) days, 
respectively. SBP and DBP in mexiletine coadministration, which were recorded 2−6 h 
after tizanidine administration in 7 patients, were lower compared to those without 
coadministration (without vs. with: 125 ± 16/82 ± 16 vs. 116 ± 13/70 ± 15 mmHg, 
P<0.02). Reductions in SBP and DBP were −9 ± 6 and −12 ± 7 mmHg, respectively. No 
patients received other medications known to inhibit tizanidine metabolism. The dosing 
schedule of drugs affecting blood pressure remained unchanged during the assessment 
period. Adverse effects caused by tizanidine were observed in 4 patients (drowsiness, 3; 
dry mouth, 1) who received 2.8−4.2 mg /kg mexiletine daily and 27.8−77.3 µg/kg 
tizanidine daily. One patient discontinued combination therapy immediately after 
mexiletine was introduced because of drowsiness. 
 
DISCUSSION 
Present results suggested that combined use of mexiletine and tizanidine produced 
drug interaction in terms of enhancing the adverse effects of tizanidine. 
Coadministration of mexiletine (2.2 mg/kg daily) increased Cmax, AUC and t1/2 of 
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tizanidine to 3.1-, 3.6- and 1.4-fold, respectively, as compared to tizanidine alone in 
healthy subjects (Fig. 1, Table 2). These changes could be due to competitive inhibition 
of mexiletine on tizanidine metabolism via CYP1A2 because the metabolic clearance of 
tizanidine was decreased to one-third by mexiletine coadministration (Table 2). The 
pharmacodynamics of tizanidine, reduction in blood pressures, was also enhanced by 
mexiletine coadministration (Table 3). Because mexiletine did not alter SBP, DBP and 
HR at the blood concentration of 0.32−1.44 µg/mL, which was higher than present study, 
blood pressure reduction in mexiletine phase was caused by tizanidine.21 
Since the smoking, a possible factor for CYP1A2 induction, has been known to affect 
pharmacokinetics of tizanidine,16 it was speculated that the magnitude for drug 
interaction of tizanidine and mexililetine might differ between smokers and 
non-smokers. Our subgroup analyses, however, revealed that the effects of mexiletine 
coadministraion on tizanidine pharmacokinetics in smokers were similar to those in 
non-smokers (data not shown). No significant difference in any pharmacokinetic 
parameters of tizanidine in terms of smoking status also did not support the 
abovementioned speculation, although the power was not sufficient to reach the 
conclusion. We, therefore, analysed the present data without mention of smoking status. 
The change in pharmacokinetics of tizanidine could be more remarkable in the 
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practical use of mexiletine, because mexiletine was administered at a dose of 3.9 
(1.8−6.0) mg/kg daily for 40 days (1−791), which is higher than that in the present 
study for healthy subjects (2.2 mg/kg daily) (Table 1). Because this dosage regimen 
produces higher steady state plasma mexiletine (0.19−0.55 µg/mL) as compared to the 
present Cmax (0.21 µg/mL), CYP1A2 activity could be strongly impaired. In this 
situation, it is considered that the adverse effects of tizanidine readily occur even at the 
standard dose. Patients who suffered the adverse effects of tizanidine such as drowsiness 
and dry mouth had received 2.8−4.2 mg /kg mexiletine daily and 27.8−77.3 µg/kg 
tizanidine daily, which seem to be higher than the doses in the present pharmacokinetic 
study (2.2 mg/kg daily and 29.4 µg/kg daily, respectively). The blood pressure reduction 
was also observed during coadministration of tizanidine and mexiletine in 6 of the 7 
patients whose blood pressures were assessed in the practical use of the combination 
therapy.  
Previous 4 studies have documented that the pharmacokinetics of tizanidine was 
altered by coadministration of several CYP1A2 inhibitors (rofecoxib, ciprofloxacin, 
fluvoxamin and oral contraceptives) in healthy subjects, whereby elevation of blood 
tizanidine concentrations and reduction in blood pressure and HR were observed 
simultaneously.1, 4, 5, 22 Effects of these CYP1A2 inhibitors on increase in plasma 
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tizanidine concentration (AUCinhibitor/AUCcontrol ratio) were different: fluvoxamine (100 
mg for 4 days), 33; ciprofloxacin (1000 mg for 3 days), 10; rofecoxib (25 mg for 4 
days), 13.6 and oral contraceptives users, 3.9.22 Comparing these data, the magnitude of 
the effects of mexiletine on the pharmacokinetics of tizanidine is comparable with oral 
contraceptives because the AUCinhibitor/AUCcontrol ratio in the present study was 3.6.  
The clinical effect of these tizanidine-related drug interactions depends on how 
frequent they are prescribed simultaneously. Because fluvoxamine and ciprofloxacin are 
now contraindicated for patients receiving tizanidine in Japan, they would no longer be 
simultaneously prescribed with tizanidine. Rofecoxib is not commercially available in 
Japan. Coadministration of oral contraceptives and mexiletine should be carefully 
monitored for tizanidine users in the future prospective study. Mexiletine was recently 
approved for treating painful neuropathies.23 Current survey of prescriptions in our 
hospital revealed that the chance for simultaneous use of mexiletine and tizanidine was 
gradually increasing (data not shown), even though caution was advised in package 
inserts for tizanidine products.  
In conclusion, mexiletine coadministration altered the pharmacokinetics of tizanidine 
in a similar magnitude to that observed with oral contraceptives, which are known 
potent CYP1A2 inhibitors. Because mexiletine and tizanidine could be coadministered 
 15 
frequently for painful neuropathies, physicians, pharmacists and other medical staff 
should consider the clinical benefit/risk evaluation of this combination therapy for 
patients with neuropathy.  
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FIGURE LEGENDS 
Fig. 1 Plasma concentrations (mean ± SD) of tizanidine in healthy subjects after 
administration of tizanidine (2 mg) alone (open circles) and coadministration of 
tizanidine (2 mg) and mexiletine (solid circles).  
 
Fig. 2 Blood pressure (mean ± SD) in healthy subjects after administration of tizanidine 
(2 mg) alone (open circles) and coadministration of tizanidine (2 mg) and mexiletine 
(solid circles).  
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Number (Male/Female) 12 (12/0)
Smoker/Non-smoker 5/7
Weight, kg 69.9 ± 12.1
Age, y 29 ± 5
Mexiletine dose, mg/kg/day 2.2 ± 0.4
Tizanidine dose, µg/kg 29.4 ± 5.0
Mexiletine pharmacokinetic parameters
Cmax, µg/mL 0.21 ± 0.04
AUC0−6, µg • h/mL 0.86 ± 0.19
Data are represented as mean ± SD.
Table 1 The profile of healthy subjects
Cmax: Peak concentration, AUC0−6: Area under the plasma concentration
versus time curve from 0 to 6 h after administration.
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Variable Tizanidine Tizanidine + Mexiletine Times of control(95% CI) P  value
Cmax, ng/mL 1.8 ± 0.8 5.3 ± 1.8 3.1 (2.6, 3.6) <0.001
tmax, h 1.2 (0.5, 2.0) 1.5 (1.0, 2.0) - -
AUC0−5, ng • h/mL 4.5 ± 2.2 15.4 ± 6.5 3.6 (2.9, 4.3) <0.001
t1/2, h 1.3 ± 0.2 1.8 ± 0.7 1.4 (1.2, 1.6) <0.05
CL/F, L/h 462 ± 209 133 ± 55 0.31 (0.23, 0.39) <0.001
CLR/F, L/h 2.6 ± 1.1 2.0 ± 1.1 0.86 (0.56, 1.17) NS
CLNR/F, L/h 460 ± 209 131 ± 55 0.31 (0.23, 0.39) <0.001
Data are represented as mean ± SD or median (range).
Table 2 Pharmacokinetic parameters of tizanidine in healthy subjects after administration of tizanidine (2 mg)
alone and coadministration of tizanidine (2 mg) and mexiletine
CI: Confidence interval, Cmax: Peak concentration, tmax: Time for Cmax, AUC0−5: Area under the plasma
concentration versus time curve from 0 to 5 h after administration, t1/2: Half-life, CL/F: Apparent oral
clearance, CLR/F: Renal clearance, CLNR/F: Non-renal clearance, NS: Not significant.
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Variable Tizanidine Tizanidine+Mexiletine Difference betweenphases (95 % CI) P  value
Systolic blood pressure
Baseline, mmHg 126 ± 6 130 ± 10 4 (−1,10) NS
Minimum, mmHg 116 ± 12 107 ± 12 −9 (−15,−3) <0.01
AUC0−5, mmHg • h 616 ± 50 586 ± 56 −30 (−55,−5) <0.05
Diastolic blood pressure
Baseline, mmHg 75 ± 8 78 ± 11 3 (−3,10) NS
Minimum, mmHg 64 ± 6 60 ± 7 −5 (−9,−1) <0.05
AUC0−5, mmHg • h 352 ± 37 328 ± 37 −24 (−46,−2) <0.05
Heart rate
Baseline, beats/min 78 ± 13 76 ± 15 −2 (−6,2) NS
Minimum, beats/min 67 ± 8 63 ± 8 −4 (−7,0) <0.05
AUC0−5, beats/min • h 365 ± 44 351 ± 45 −14 (−29,0) <0.05
Data are represented as mean ± SD.
CI: Confidence interval, AUC0−5: Area under the blood pressure or heart rate versus time curve from 0 to 5 h
after administration, NS: Not significant.
Table 3 Changes in cardiovascular pharmacodynamic parameters in healthy subjects after administration of
tizanidine alone and coadministration of tizanidine and mexiletine
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
